Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Summary

A window of opportunity study which would allow brief treatment of HPV negative SCCHN with a CDK4/6 inhibitor, in the pre-operative setting, with biomarker analyses of pre and post treatment tissue. Given that the standard treatment for this population is surgical resection, this would not impact or alter standard therapy for this population. The goal will be to learn more about the alterations in pRB1 levels, as well as other signaling markers, in order to be able to eventually plan a biomarker driven treatment study.

Timeline

Start

2018-04-02

Primary completion

2018-11-12

Completion

2019-01-10

Drugs

Indications